Globus Medical Inc
Change company Symbol lookup
Select an option...
GMED Globus Medical Inc
DX Dynex Capital Inc
BMO Bank of Montreal
FPRX Five Prime Therapeutics Inc
VTR Ventas Inc
PENN Penn National Gaming Inc
SUN Sunoco LP
SWKS Skyworks Solutions Inc
VOO Vanguard S&P 500 ETF

Health Care : Health Care Equipment & Supplies | Mid Cap Growth
Company profile

Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders. It is focused on products to treat patients with spine disorders. The Company's products fall under categories, which include Innovative Fusion and Disruptive Technologies. The Innovative Fusion category products include fusion products to treat spinal disorders for the entire spine, and they can be used in various surgical approaches. The Disruptive Technologies category represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. QUARTEX is its Occipito-Cervico-Thoracic (OCT) stabilization system. QUARTEX features a threading locking cap to enable low-torque. The Company's portfolio of approved and pipeline Disruptive Technology products includes products that allow for minimally invasive surgical (MIS) techniques.

Closing Price
Day's Change
-1.06 (-1.93%)
B/A Size
Day's High
Day's Low

10-day average volume:

Hilton's stock set to rally after profit beat, but revenue fell shy as RevPAR dropped 23%

6:16 am ET May 7, 2020 (MarketWatch)

Hilton Worldwide Holdings Inc. (HLT) reported Thursday a first-quarter adjusted profit that beat expectations, but revenue that fell shy of forecasts as the COVID-19 pandemic led to decreases in occupancy and management and franchise fees. The stock was indicated up over 2% in premarket trading. Net income fell to $18 million, or 6 cents a share, from $158 million, or 54 cents a share, in the year-ago period. Excluding non-recurring items, such as impairment losses and amortization, adjusted earnings per share slipped to 74 cents from 80 cents but was above the FactSet consensus of 51 cents. Revenue declined 12.9% to $1.92 billion, just below the FactSet consensus of $1.93 billion. Revenue per available room (RevPAR) dropped 22.6% to $76.16, as occupancy fell 14.3% to 56.0%. "With the exception of the Asia Pacific region, Hilton's first quarter results were not significantly impacted by the COVID-19 pandemic until March 2020, with occupancy roughly flat through February in the Americas and Europe, Middle East and Africa (EMEA) regions," said Chief Executive Christopher Nassetta. Occupancy in Asia Pacific fell 27.6% to 38.1%. The stock has tumbled 36.2% year to date through Wednesday, while the S&P 500 has lost 11.8%.

-Tomi Kilgore; 415-439-6400;

(END) Dow Jones Newswires

May 07, 2020 06:16 ET (10:16 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.